(EHAB) Enhabit - Ratings and Ratios
Home Health, Hospice, Therapy, Skilled Nursing, Chronic Care
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 54.4% |
| Value at Risk 5%th | 73.0% |
| Relative Tail Risk | -18.46% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.59 |
| Alpha | 15.90 |
| CAGR/Max DD | -0.21 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.587 |
| Beta | 0.659 |
| Beta Downside | 0.768 |
| Drawdowns 3y | |
|---|---|
| Max DD | 59.30% |
| Mean DD | 38.97% |
| Median DD | 42.13% |
Description: EHAB Enhabit December 27, 2025
Enhabit, Inc. (NYSE: EHAB) operates a nationwide network of home health and hospice providers, delivering services such as skilled nursing, wound care, infusion therapy, and rehabilitation, as well as comprehensive end-of-life support that includes pain management, counseling, and spiritual care. The company rebranded from Encompass Health Home Health Holdings in March 2022 and is headquartered in Dallas, Texas.
As of Q3 2024, Enhabit reported total revenue of $1.12 billion, up 7 % year-over-year, driven primarily by higher case-mix intensity and a 4 % increase in patient days. Adjusted EBITDA margin stood at 6.8 %, reflecting ongoing cost-control initiatives amid a tight labor market. The firm’s average daily census (ADC) grew to 14.5 patients per agency, a metric that tracks utilization efficiency in the home-health sector.
Key industry drivers include the U.S. aging demographic-people aged 65+ are projected to reach 21 % of the population by 2030-alongside rising Medicare Advantage enrollment, which often favors home-based care to reduce hospital costs. Conversely, the sector faces headwinds from a persistent skilled-nurse shortage and potential policy shifts in Medicare reimbursement rates.
For a deeper dive into EHAB’s valuation metrics, see the ValueRay platform.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: -11.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.68 > 1.0 |
| NWC/Revenue: 7.46% < 20% (prev 6.30%; Δ 1.17% < -1%) |
| CFO/TA 0.05 > 3% & CFO 62.2m > Net Income -11.9m |
| Net Debt (459.6m) to EBITDA (59.2m): 7.76 < 3 |
| Current Ratio: 1.58 > 1.5 & < 3 |
| Outstanding Shares: last quarter (51.1m) vs 12m ago 1.79% < -2% |
| Gross Margin: 48.43% > 18% (prev 0.47%; Δ 4797 % > 0.5%) |
| Asset Turnover: 82.75% > 50% (prev 79.52%; Δ 3.22% > 0%) |
| Interest Coverage Ratio: 0.93 > 6 (EBITDA TTM 59.2m / Interest Expense TTM 36.5m) |
Altman Z'' 1.17
| A: 0.06 (Total Current Assets 213.7m - Total Current Liabilities 135.5m) / Total Assets 1.23b |
| B: 0.11 (Retained Earnings 132.4m / Total Assets 1.23b) |
| C: 0.03 (EBIT TTM 33.8m / Avg Total Assets 1.27b) |
| D: 0.21 (Book Value of Equity 132.9m / Total Liabilities 631.0m) |
| Altman-Z'' Score: 1.17 = BB |
Beneish M -3.15
| DSRI: 0.98 (Receivables 148.7m/150.9m, Revenue 1.05b/1.04b) |
| GMI: 0.96 (GM 48.43% / 46.56%) |
| AQI: 0.98 (AQ_t 0.77 / AQ_t-1 0.78) |
| SGI: 1.01 (Revenue 1.05b / 1.04b) |
| TATA: -0.06 (NI -11.9m - CFO 62.2m) / TA 1.23b) |
| Beneish M-Score: -3.15 (Cap -4..+1) = AA |
ValueRay F-Score (Strict, 0-100) 45.00
| 1. Piotroski: 4.50pt |
| 2. FCF Yield: 5.74% |
| 3. FCF Margin: 5.52% |
| 4. Debt/Equity: 0.91 |
| 5. Debt/Ebitda: 7.76 |
| 6. ROIC - WACC: -2.34% |
| 7. RoE: -2.18% |
| 8. Revenue Trend: -67.53% |
| 9. EPS Trend: data missing |
What is the price of EHAB shares?
Over the past week, the price has changed by -0.48%, over one month by +10.19%, over three months by +20.98% and over the past year by +22.99%.
Is EHAB a buy, sell or hold?
- StrongBuy: 1
- Buy: 0
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the EHAB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11.8 | 13.2% |
| Analysts Target Price | 11.8 | 13.2% |
| ValueRay Target Price | 10.8 | 3.7% |
EHAB Fundamental Data Overview January 26, 2026
P/S = 0.522
P/B = 0.9634
Revenue TTM = 1.05b USD
EBIT TTM = 33.8m USD
EBITDA TTM = 59.2m USD
Long Term Debt = 441.5m USD (from longTermDebt, last quarter)
Short Term Debt = 35.2m USD (from shortTermDebt, last quarter)
Debt = 516.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 459.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.01b USD (546.9m + Debt 516.5m - CCE 56.9m)
Interest Coverage Ratio = 0.93 (Ebit TTM 33.8m / Interest Expense TTM 36.5m)
EV/FCF = 17.41x (Enterprise Value 1.01b / FCF TTM 57.8m)
FCF Yield = 5.74% (FCF TTM 57.8m / Enterprise Value 1.01b)
FCF Margin = 5.52% (FCF TTM 57.8m / Revenue TTM 1.05b)
Net Margin = -1.14% (Net Income TTM -11.9m / Revenue TTM 1.05b)
Gross Margin = 48.43% ((Revenue TTM 1.05b - Cost of Revenue TTM 540.3m) / Revenue TTM)
Gross Margin QoQ = 48.48% (prev 46.94%)
Tobins Q-Ratio = 0.82 (Enterprise Value 1.01b / Total Assets 1.23b)
Interest Expense / Debt = 1.61% (Interest Expense 8.30m / Debt 516.5m)
Taxrate = 21.62% (3.20m / 14.8m)
NOPAT = 26.5m (EBIT 33.8m * (1 - 21.62%))
Current Ratio = 1.58 (Total Current Assets 213.7m / Total Current Liabilities 135.5m)
Debt / Equity = 0.91 (Debt 516.5m / totalStockholderEquity, last quarter 566.8m)
Debt / EBITDA = 7.76 (Net Debt 459.6m / EBITDA 59.2m)
Debt / FCF = 7.95 (Net Debt 459.6m / FCF TTM 57.8m)
Total Stockholder Equity = 546.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.94% (Net Income -11.9m / Total Assets 1.23b)
RoE = -2.18% (Net Income TTM -11.9m / Total Stockholder Equity 546.5m)
RoCE = 3.42% (EBIT 33.8m / Capital Employed (Equity 546.5m + L.T.Debt 441.5m))
RoIC = 2.56% (NOPAT 26.5m / Invested Capital 1.03b)
WACC = 4.90% (E(546.9m)/V(1.06b) * Re(8.34%) + D(516.5m)/V(1.06b) * Rd(1.61%) * (1-Tc(0.22)))
Discount Rate = 8.34% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 57.8m)
Revenue Correlation: -67.53 | Revenue CAGR: -1.23% | SUE: N/A | # QB: 0
Additional Sources for EHAB Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle